Tj. Babineau et al., RANDOMIZED PHASE I II TRIAL OF A MACROPHAGE-SPECIFIC IMMUNOMODULATOR (PGG-GLUCAN) IN HIGH-RISK SURGICAL PATIENTS/, Annals of surgery, 220(5), 1994, pp. 601-609
Objective The safety and efficacy of PGG-glucan in surgical patients a
t high risk for postoperative infection who underwent major thoracic o
r abdominal surgery were determined. Summary Background Data Recent st
udies have reported a 25% to 27% infectious complication rate in patie
nts undergoing major surgery with an average cost per infected patient
of $12,000. The efficacy of PGG-glucan pretreatment in prevention of
sepsis has been demonstrated in rodent models for gram-negative and gr
am-positive bacterial and yeast infections. In vitro studies have demo
nstrated enhanced microbial killing by monocytes and neutrophils in he
althy volunteers after PGG-glucan administration. Thus, PGG-glucan may
play a role in decreasing the infectious complication rate in patient
s undergoing major surgery. Methods A double-blind, placebo-controlled
randomized study was performed in 34 high-risk patients undergoing ma
jor abdominal or thoracic surgery. Results There were no adverse drug
experiences associated with PGG-glucan infusion. Patients who received
PGG-glucan had significantly fewer infectious complications (3.4 infe
ctions per infected patient vs. 1.4 infections per infected patient, p
= 0.05), decreased intravenous antibiotic requirement (10.3 days vs.
0.4 days, p = 0.04) and shorter intensive care unit length of stay (3.
3 days vs. 0.1 days, p = 0.03). Conclusions PGG-glucan is safe and app
ears to be effective in the further reduction of the morbidity and cos
t of major surgery.